

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
08 May 2025 (08.05.2025)



(10) International Publication Number
WO 2025/096949 A1

(51) International Patent Classification:

A61K 31/56 (2006.01) A61K 47/28 (2006.01)
A61K 31/57 (2006.01) A61K 47/06 (2006.01)

(21) International Application Number:

PCT/US2024/054126

(22) International Filing Date:

01 November 2024 (01.11.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/547,217 03 November 2023 (03.11.2023) US
63/633,336 12 April 2024 (12.04.2024) US

(71) Applicants: TAIWAN LIPOSOME COMPANY, LTD.

[CN/CN]; 11F-1, No. 3, Park Street, Nangang District, Taipei City, Taiwan 11503 (CN). **TLC BIOPHARMACEUTICALS, INC.** [US/US]; 611 Gateway Blvd., Suite 830, South San Francisco, California 94080 (US).

(72) Inventors: SHIH, Sheue-Fang; c/o TAIWAN LIPOSOME

COMPANY, LTD., 11F-1, No. 3, Park Street, Nangang District, Taipei City, Taiwan 11503 (CN). **TAI, Tien-Tzu;** c/o TAIWAN LIPOSOME COMPANY, LTD., 11F-1, No. 3, Park Street, Nangang District, Taipei City, Taiwan 11503 (CN). **KAO, Kai-Ling;** c/o TAIWAN LIPOSOME COMPANY, LTD., 11F-1, No. 3, Park Street, Nangang District,

Taipei City, Taiwan 11503 (CN). **HUANG, Siao-Ning;** c/o TAIWAN LIPOSOME COMPANY, LTD., 11F-1, No. 3, Park Street, Nangang District, Taipei City, Taiwan 11503 (CN). **SPENCER-GREEN, George;** c/o TLC BIOPHARMACEUTICALS, INC., 611 Gateway Blvd., Suite 830, South San Francisco, California 94080 (US).

(74) Agent: **WAUTERS, Hui C.** et al.; SUGHRUE MION, PLLC, 2000 Pennsylvania Ave., N.W., Suite 9000, Washington, District of Columbia 20006 (US).


(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,

(54) Title: LIPOSOMAL COMPOSITION OF INTRA-ARTICULAR CORTICOSTEROID FOR PAIN CONTROL



Abbreviations: BL = Baseline; DSP = dexamethasone sodium phosphate; Rand = Randomization; SCR = Screening; W = Week.

Fig. 1

(57) Abstract: Provided is a method for treating joint pain in a subject with osteoarthritis in long term. The method includes administering intra-articularly repeated doses of a liposomal composition comprising an effective amount of intra-articular corticosteroid or a pharmaceutically acceptable salt thereof to the subject with osteoarthritis. Achieved is robustness of an extended efficacy response to an intra-articular corticosteroid treatment for over one year without any signs or symptoms associated with adrenal insufficiency in the subject.

[Continued on next page]

DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))